Clinical Observation Of Apatinib In Advanced Lung Cancer With Multi-line Chemotherapy Failure

Background and PurposeThe early symptoms and signs of lung cancer are not obvious,most patients are in the late stage of disease.But traditional chemotherapy and radiotherapy,lack of specificity,toxic side effects,patients can not tolerate long-term.Targeted drugs have the advantages of convenient drug delivery and small side effects.But in the ointment,it is only targeted at some of the patients with gene mutation,and there is resistance.As a domestic antiangiogenic drug,it has been found to be effective in all kinds of solid tumors,but reports about it are still uncommon.In this study,82 patients with advanced lung cancer were analyzed to find out the efficacy,adverse effects and prognostic factors of the treatment.Meterials and MethodsRetrospective analysis of 82 patients with advanced lung cancer,according to the treatment of patients divided into the apatinib treatment group 42 cases,the remaining 40 cases were divided into simple chemotherapy group 30 cases and the best support treatment group 10 cases.The results of three groups were evaluated,such as mPFS,disease control rate,secondary observation index as related adverse reaction and prognostic factors.Results1.Survival: The mPFS of apatinib group,chemotherapy group and the support treatment group were 4.1m,3.0m and 1.6m.Compared with the support group,both the apatinib group and chemotherapy group were able to benefit from mPFS,but apatinib group benefited the most and extended 2.5m.The control rate of DCR in the apatinib group was 76.2%,higher than 46.7% in the chemotherapy group and the support group 30%,(p<0.05).2.Adverse reactions in the apatinib treatment group: There were 11 cases of hand-foot syndrome(26.2%),bone marrow suppression in 6 cases(14.3%),hypertension in 5 cases(11.9%),proteinuria in 2 cases(0.05%),weakness in 10 cases(23.8%),and loss of appetite in 8 cases(19%).For different adverse reactions,give symptomatic treatment,can be alleviated.The adverse reactions in the chemotherapy group were bone marrow inhibition in 24 cases(80%),nausea and appetite loss in 17 cases(56.7%)and weakness in 15 cases(50%).The incidence of blood-related adverse reactions in the chemotherapy group was high.3.Univariate analysis results: The degree of tissue differentiation,ECOG score,degree of adverse reactions,anatomic location,number of metastases were all related to the prognosis of patients.Gender,age,pathological type,etc.have nothing to do with the prognosis.4.Multivariate analysis results: The degree of tissue differentiation and anatomic location were independent factors in the treatment of advanced lung cancer with apatinib.ConclusionFor patients with advanced lung cancer who failed with multiline therapy,taking apatinib can achieve a certain survival benefit compared to optimal supportive care.Compared with the chemotherapy group,the apatinib group had mild side effects,good patient tolerance,and longer survival time.The prognosis of highly differentiated,peripheral lung cancer is better.